Pharsight

Zelboraf is owned by Hoffmann La Roche.

Zelboraf contains Vemurafenib.

Zelboraf has a total of 6 drug patents out of which 0 drug patents have expired.

Zelboraf was authorised for market use on 17 August, 2011.

Zelboraf is available in tablet;oral dosage forms.

Zelboraf can be used as zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation; treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test.

The generics of Zelboraf are possible to be released after 06 June, 2032.

Application	Filing Date	Opposition Party	Legal Status
EP15171526A	2018-10-05	Generics (UK) Ltd	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8143271	HOFFMANN LA ROCHE	NA	Jun, 2026 (3 years from now)
US7504509	HOFFMANN LA ROCHE	Compounds and methods for development of Ret modulators	Oct, 2026 (3 years from now)
US7863288	HOFFMANN LA ROCHE	NA	Jun, 2029 (6 years from now)
US8741920	HOFFMANN LA ROCHE	Process for the manufacture of pharmaceutically active compounds	Jul, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8470818	HOFFMANN LA ROCHE	NA	Aug, 2026 (3 years from now)
US9447089	HOFFMANN LA ROCHE	Compositions and uses thereof	Jun, 2032 (9 years from now)

Do you want to check out ZELBORAF patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Nov 6, 2024

Drugs and Companies using VEMURAFENIB ingredient

Market Authorisation Date: 17 August, 2011

Treatment: Zelboraf is indicated for the treatment of patients with erdheim-chester disease with braf v600 mutation; Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as dete...

Dosage: TABLET;ORAL